For non‐small lung cancer cells, CD47 expression was upregulated in the cancer cells' resistance to EGFR inhibitor treatment, and CD47 blockade increased the clearance of the resistant cells by phagocytes.[19] Given that receptor tyrosine kinase‐targeted therapies are prevalent in treating many types of cancer, our findings elucidate a novel mechanism underlying CD47 expression in RTK‐activated tumor cells and underscore the synergetic tumor inhibition effect elicited by combined treatment with EGFR inhibitors and CD47‐SIRPα blockade. The gene discussed is CD47; the disease is cancer.